Oncogene Functions of FHL2 Are Independent from NF-κBIα in Gastrointestinal Cancer

详细信息    查看全文

• 作者：Liang Qiao (1)
  Yan Wang (1)
  Roberta Pang (1)
  Jide Wang (1)
  Yun Dai (1)
  Juan Ma (1)
  Qing Gu (1)
  Zesong Li (1)
  Yusheng Zhang (1)
  Bing Zou (1)
  H. Y. Lan (1)
  Benjamin C. Y. Wong (1) (2)
  
• 关键词：FHL2 ; NF ; κB ; NF ; κBIα ; Interaction ; Gastric cancer ; Colon cancer
• 刊名：Pathology & Oncology Research
• 出版年：2009
• 出版时间：March 2009
• 年：2009
• 卷：15
• 期：1
• 页码：31-36
• 全文大小：185KB
• 参考文献：1. Chan KK, Tsui SK, Lee SM, Luk SC, Liew CC, Fung KP, Waye MM, Lee CY (1998) Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart. Gene 210:345-50 CrossRef
  2. Genini M, Schwalbe P, Scholl FA, Remppis A, Mattei MG, Schafer BW (1997) Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma. DNA Cell Biol 16:433-42 CrossRef
  3. Scholl FA, McLoughlin P, Ehler E, de Giovanni C, Schafer BW (2000) DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J Cell Biol 151:495-06 CrossRef
  4. Kinoshita M, Nakagawa T, Shimizu A, Katsuoka Y (2005) Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Int J Urol 12:390-97 CrossRef
  5. Gabriel B, Mildenberger S, Weisser CW, Metzger E, Gitsch G, Schule R, Muller JM (2004) Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res 24:921-27
  6. Wang J, Yang Y, Xia HH, Gu Q, Lin MC, Jiang B, Peng Y, Li G, An X, Zhang Y, Zhuang Z, Zhang Z, Kung HF, Wong BC (2007) Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 132:1066-076 CrossRef
  7. Wei Y, Renard CA, Labalette C, Wu Y, Levy L, Neuveut C, Prieur X, Flajolet M, Prigent S, Buendia MA (2003) Identification of the LIM protein FHL2 as a coactivator of b-catenin. J Biol Chem 278:5188-194 CrossRef
  8. Yan J, Zhu J, Zhong H, Lu Q, Huang C, Ye Q (2003) BRCA1 interacts with FHL2 and enhances FHL2 transactivation function. FEBS Lett 553:183-89 CrossRef
  9. Martin BT, Kleiber K, Wixler V, Raab M, Zimmer B, Kaufmann M, Strebhardt K (2007) FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle 6:1779-788
  10. Muller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch C, Buettner R, Schule R (2000) FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J 19:359-69 CrossRef
  11. Fimia GM, De Cesare D, Sassone-Corsi P (2000) A family of LIM-only transcriptional coactivators: tissue-specific expression and selective activation of CREB and CREM. Mol Cell Biol 20:8613-622 CrossRef
  12. Samson T, Smyth N, Janetzky S, Wendler O, Muller JM, Schule R, von der Mark H, von der Mark K, Wixler V (2004) The LIM-only proteins FHL2 and FHL3 interact with a- and b-subunits of the muscle a7b1 integrin receptor. J Biol Chem 279:28641-8652 CrossRef
  13. Tanahashi H, Tabira T (2000) Alzheimer’s disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein. Hum Mol Genet 9:2281-289
  14. Purcell NH, Darwis D, Bueno OF, Muller JM, Schule R, Molkentin JD (2004) Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol Cell Biol 24:1081-095 CrossRef
  15. Morlon A, Sassone-Corsi P (2003) The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc Natl Acad Sci USA 100:3977-982 CrossRef
  16. Chen D, Xu W, Bales E, Colmenares C, Conacci-Sorrell M, Ishii S, Stavnezer E, Campisi J, Fisher DE, Ben-Ze’ev A, Medrano EE (2003) SKI activates Wnt/b-catenin signaling in human melanoma. Cancer Res 63:6626-634
  17. Labalette C, Renard CA, Neuveut C, Buendia MA, Wei Y (2004) Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and b-catenin. Mol Cell Biol 24:10689-0702 CrossRef
  18. Yang Y, Hou H, Haller EM, Nicosia SV, Bai W (2005) Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J 24:1021-032 CrossRef
  19. Nair SS, Guo Z, Mueller JM, Koochekpour S, Qiu Y, Tekmal RR, Schüle R, Kung HJ, Kumar R, Vadlamudi RK (2007) Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol 21:613-24 CrossRef
  20. Stilo R, Leonardi A, Formisano L, Di Jeso B, Vito P, Liguoro D (2002) TUCAN/CARDINAL and DRAL participate in a common pathway for modulation of NF-kB activation. FEBS Lett 521:165-69 CrossRef
  21. Kleiber K, Strebhardt K, Martin BT (2007) The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res 27:55-1
  22. Bai S, Kitaura H, Zhao H, Chen J, Müller JM, Schüle R (2005) FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. J Clin Invest 115:2742-751 CrossRef
  23. James P, Halladay J, Craig EA (1996) Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast. Genetics 144:1425-436
  24. Ding GR, Honda N, Nakahara T, Tian F, Yoshida M, Hirose H, Miyakoshi J (2003) Radiosensitization by inhibition of IkB-a phosphorylation in human glioma cells. Radiat Res 160:232-37 CrossRef
  25. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ (2000) Proteasome inhibition measurements: clinical application. Clin Chem 46:673-83
  26. Gao J, Pfeifer D, He LJ, Qiao F, Zhang Z, Arbman G, Wang ZL, Jia CR, Carstensen J, Sun XF (2007) Association of NFKBIA polymorphism with colorectal cancer risk and prognosis in Swedish and Chinese populations. Scand J Gastroenterol 42:345-50 CrossRef
  
• 作者单位：Liang Qiao (1)
  Yan Wang (1)
  Roberta Pang (1)
  Jide Wang (1)
  Yun Dai (1)
  Juan Ma (1)
  Qing Gu (1)
  Zesong Li (1)
  Yusheng Zhang (1)
  Bing Zou (1)
  H. Y. Lan (1)
  Benjamin C. Y. Wong (1) (2)
  
  1. Department of Medicine, The University of Hong Kong, Hong Kong, China
  2. Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China
  
• ISSN：1532-2807

文摘

Four and a half of LIM-only protein 2 (FHL2) is an adaptor protein that can interact with many transcription factors and thus plays a variety of biological functions. Previous studies by our group have demonstrated that suppression of FHL2 was capable of inducing tumor cell differentiation, and inhibiting the growth of experimental gastric and colon cancers. Therefore, FHL2 appears to function as an oncogene. In order to further explore the mechanisms of how FHL2 is involved in tumorigenesis, we attempted to test whether FHL2 has any direct association with nuclear factor (NF-κB), the most important transcription factor involved in apoptosis, inflammation, and carcinogenesis. Using an Yeast Two Hybrid (Y2H) screening system, we have shown that FHL2 may have an interaction with NF-κBIα, the coding gene for IκBα which is the most potent endogenous inhibitor for NF-κB activation. However, subsequent studies using co-immunoprecipitation and co-localization failed to confirm the Y2H finding. Down-regulation of FHL2 by FHL2-siRNA down-regulated the expression of NF-κB p65. We therefore concluded that under the physiological condition, FHL2 may activate NF-κB pathway, even though such an activation may not be mediated by a direct binding of FHL2 to NF-κB inhibitor protein IκB.